The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Exploiting the lymphatic system for next generation vaccine development . Vaccination is the most successful and cost-effective means of combating infectious diseases. This project will look at how vaccine adjuvants work and will help the development of new vaccines against infections in both animals and man. It will also promote the training of Australian scientists in the field of vaccine research and development.
Dissecting the physiology of multipotent mesenchymal stromal cells to develop vaccine candidates for respiratory disease. The project aims to gain an understanding of how a type of adult stem cell inhibits immune responses that cause asthma. The project will produce new stem cell products and facilitate the design of a vaccine for asthma and other respiratory diseases, which would greatly reduce the burden of such conditions.
Cellulosic and paper-based biosensors for blood analysis. Testing the blood compatibility of an Australian evacuated for surgery; measuring the iron content from India for anemia treatment; identifying the outbreak of malaria in Pakistan; measuring prostate specific antigen/blood screening in your home. These are novel applications for paper biosensors, which will improve health and create new jobs in Australia.
Biophysical identification of natural human antibody targets. A natural human antibody, PAT-SM6, isolated using technology developed by the partner organisation (Patrys), offers promise as a therapy to reduce mortalities due to cancer, the leading cause of death in Australia. The novelty of the approach pioneered by Patrys is the direct production of human antibodies which avoids undesirable side effects associated with the use of antibodies containing non-human components. This project is to ....Biophysical identification of natural human antibody targets. A natural human antibody, PAT-SM6, isolated using technology developed by the partner organisation (Patrys), offers promise as a therapy to reduce mortalities due to cancer, the leading cause of death in Australia. The novelty of the approach pioneered by Patrys is the direct production of human antibodies which avoids undesirable side effects associated with the use of antibodies containing non-human components. This project is to discover the specificity of PAT-SM6 for proteins and protein complexes and how these interactions lead to tumour cell death. This work will enhance the effectiveness of human antibody therapies and help in the development of this fast growing area within the biotechnology industry in Australia.Read moreRead less
Exploring the immunomodulatory potential of Natural Killer T cells. Natural Killer T cells (NKT cells) are an innate-like population of T cells that recognise a range of lipid based antigens when bound to the antigen-presenting molecule, CD1d. Once activated, NKT cells rapidly secrete a variety of cytokines. This project, in partnership with Vaxine Pty Ltd, aims to gain a basic understanding of NKT recognition of lipids and NKT cell activation by lipids. The project aims to use a combination of ....Exploring the immunomodulatory potential of Natural Killer T cells. Natural Killer T cells (NKT cells) are an innate-like population of T cells that recognise a range of lipid based antigens when bound to the antigen-presenting molecule, CD1d. Once activated, NKT cells rapidly secrete a variety of cytokines. This project, in partnership with Vaxine Pty Ltd, aims to gain a basic understanding of NKT recognition of lipids and NKT cell activation by lipids. The project aims to use a combination of cellular immunology and structural biology to gain insight into NKT cell agonism.Read moreRead less
Intracellular trafficking and function of a recycling receptor which prolongs the serum half-life of novel therapeutic proteins. The life span of recombinant engineered proteins for therapeutic use is a critical factor in their effectiveness, ease of clinical application and cost. This project will exploit interactions with a natural receptor, which prolongs the lifespan of serum proteins, to enhance survival of therapeutic engineered proteins.